Skip to content

US · EOLS · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Evolus, Inc. (EOLS) intrinsic value and stock valuation

$6.52as of 2026-11-21 · Mkt cap 499.84M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Evolus, Inc. DCF and intrinsic value

InvestorsCraft values EOLS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from EOLS’s statements →

Evolus, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Newport Beach, CA 92660 evolus.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$297.2M+39.4% 5y CAGRd
20152025
Net income
-$-51.64M
20152025
Free cash flow
-$-50.72M
20152025
Total equity
-$-23.11M
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$297.2M$266.3M$202.1M$148.6M$99.7M
Operating income-$-37.6M-$-34.41M-$-49.23M-$-65.33M-$-44.41M
Net income-$-51.64M-$-50.42M-$-61.69M-$-74.41M-$-46.81M
EPSd-$-800.99K-$-812.96K-$-1.08M-$-1.33M-$-940.53K
Operating cash flow-$-42.27M-$-18M-$-34.01M-$-84.91M-$-33.39M
Capital expenditure-$-8.45M-$-1.47M-$-1.63M-$-2.94M-$-970K
Free cash flow-$-50.72M-$-19.47M-$-35.63M-$-87.85M-$-34.36M
Total assets$225.9M$232.6M$189M$178M$257.5M
Total debt$155M$130M$126.6M$74.4M$74.7M
Net debt$101.2M$43M$63.7M$20.5M-$-71.51M
Total equity-$-23.11M$5.52M-$-20.69M$18.5M$81.9M
Cash and short-term investments$53.8M$87M$62.8M$53.9M$146.3M
Income statement
20252024202320222021
Revenue$297.2M$266.3M$202.1M$148.6M$99.7M
Cost of revenue$104.4M$84M$61.6M$58.8M$43.5M
Gross profit$192.8M$182.3M$140.5M$89.8M$56.1M
Research and development expenses$9.58M$9.17M$15.4M$6.74M$2.06M
Selling, general and administrative expenses$220.8M$198M$164.9M$141.8M$112.1M
Other expenses$0.00$9.52M$9.39M$6.52M-$-13.59M
Operating expenses$230.4M$216.7M$189.8M$155.1M$100.5M
Cost and expenses$334.8M$300.7M$251.3M$214M$144.1M
Interest income$1.93M$3.26M$860K$120K$0.00
Interest expense$19.7M$18.7M$13.8M$9.1M$1.4M
Depreciation and amortization$8.74M$6.02M$5.87M$3.72M$6.31M
Ebitda-$-22.53M-$-25M-$-41.81M-$-53.85M-$-39.06M
Operating income-$-37.6M-$-34.41M-$-49.23M-$-65.33M-$-44.41M
Total other income/expenses, net-$-13.36M-$-15.35M-$-12.28M-$-8.99M-$-2.36M
Income before tax-$-50.96M-$-49.76M-$-61.51M-$-74.32M-$-46.77M
Income tax expense$680K$660K$180K$100K$40K
Net income-$-51.64M-$-50.42M-$-61.69M-$-74.41M-$-46.81M
Weighted average shares outstanding$64.5M$62M$56.9M$56.1M$49.8M
Weighted average diluted shares outstanding$64.5M$62M$56.9M$56.1M$49.8M
Balance sheet
20252024202320222021
Cash and short-term investments$53.8M$87M$62.8M$53.9M$146.3M
Net receivables$54.7M$47.7M$30.5M$22.5M$14.7M
Inventory$27M$12.2M$11M$18.9M$1.76M
Total current assets$142.9M$151.3M$112.4M$100.8M$178.8M
Property, plant and equipment, net$12.5M$10.4M$7.85M$4.56M$4.09M
Goodwill and intangible assets$69.3M$70M$68.3M$69.8M$71.8M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$83M$81.2M$76.6M$77.2M$78.7M
Total assets$225.9M$232.6M$189M$178M$257.5M
Accounts payable$23.4M$9.24M$4.27M$8.94M$6.09M
Short-term debt$2.53M$1.72M$1.38M$1.32M$1.26M
Deferred revenue$11.6M$14.5M$11M$9.01M$7.93M
Total current liabilities$75.3M$63M$48.3M$46.5M$57.7M
Long-term debt$152.5M$128.3M$125.2M$73.1M$73.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$173.7M$164.1M$161.4M$113M$117.9M
Capital lease obligations$8.9M$8.47M$6.19M$2.54M$3.52M
Total liabilities$249M$227.1M$209.7M$159.5M$175.6M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-661.04M-$-609.4M-$-558.98M-$-497.29M-$-422.88M
Accumulated other comprehensive income (loss)-$-160K-$-910K-$-430K-$-340K$0.00
Total equity-$-23.11M$5.52M-$-20.69M$18.5M$81.9M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$155M$130M$126.6M$74.4M$74.7M
Net debt$101.2M$43M$63.7M$20.5M-$-71.51M
Cash flow statement
20252024202320222021
Net income-$-51.64M-$-50.42M-$-61.69M-$-74.41M-$-46.81M
Depreciation and amortization$8.74M$6.02M$5.87M$4.5M$6.31M
Stock-based compensation$20.7M$22.3M$16.5M$10.8M$9.58M
Change in working capital-$-22.48M-$-6.6M-$-5.89M-$-34.25M-$-11.54M
Accounts receivable-$-11.51M-$-19.6M-$-9.52M-$-9.39M-$-5.57M
Inventory-$-11.12M$3.25M$4.19M-$-10.69M-$-2.98M
Accounts payable$10.1M$390K-$-1.02M$970K-$-790K
Net cash provided by operating activities-$-42.27M-$-18M-$-34.01M-$-84.91M-$-33.39M
Investments in property, plant and equipment-$-3.44M-$-1.47M-$-470K-$-1.62M-$-390K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-8.45M-$-4.82M-$-1.63M-$-2.94M$4.03M
Common stock issued$1.16M$51.2M$0.00$0.00$103.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.3M$47.4M$44.6M-$-4.15M$73.1M
Net change in cash-$-33.13M$24.1M$8.92M-$-92.33M$43.7M
Cash at end of period$53.8M$87M$62.8M$53.9M$146.3M
Operating cash flow-$-42.27M-$-18M-$-34.01M-$-84.91M-$-33.39M
Capital expenditure-$-8.45M-$-1.47M-$-1.63M-$-2.94M-$-970K
Free cash flow-$-50.72M-$-19.47M-$-35.63M-$-87.85M-$-34.36M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Evolus, Inc.

        Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

        CEO
        David Moatazedi
        Employees
        334
        Beta
        1.32

        Explore

        Frequently asked questions

        What is the intrinsic value of Evolus, Inc. (EOLS)?

        Evolus, Inc. (EOLS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EOLS undervalued?

        EOLS trades at a price of $6.52 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.